Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $45
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Patrick Donnelly maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $24 to $45.
Citigroup analyst Patrick Donnelly maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $24 to $45.